Influences
Medical materials: The legal and financial structuring of Dislog Medical Devices finalized
By grouping six specialized subsidiaries, the Dislog group aims to strengthen its position in a high-potential market while preparing its expansion on the African scale.
Dislog Group accelerates its diversification with the launch of Dislog Medical Devices (DMD), a new entity grouping six specialized subsidiaries: Megaflex, Afrobiomedic, Farmalac, Eramedic, Promedstore Imaging, and Scomedica. This build-up operation illustrates the group’s desire to establish itself sustainably in the medical devices market, a rapidly growing sector with high impact.
Several key steps mark this strategic project: a fundraising of 700 million dirhams aimed at supporting the development of DMD in Morocco and internationally over the next two years, as well as a capital opening of 11% to the management teams of the six subsidiaries. Among the major acquisitions, the group finalized the 100% takeover of Megaflex and Scomedica by buying out the shares of their founders Nacer Amrani and Dr. Ali Squalli respectively.
On the managerial level, Mehdi Bouamrani is appointed chairman of the board, while Karim Hajj Riffi takes the helm as CEO. To steer the strategy, a committee composed of the main shareholder executives has been set up, ensuring both unified governance and the sustainability of local expertise, with the founders remaining in charge of their subsidiaries.
In the interest of cohesion, an integration seminar brought together 250 employees from the different entities yesterday to strengthen commitment around the common goal: reaching a turnover of 2 billion dirhams by 2028.
Strong financial support for a continental ambition
This project benefits from significant financial backing: MCP and CDG Invest Growth provide 540 million dirhams, or 35% of the capital, while the founders invest 190 million (11%). Dislog Group retains the majority of the capital and ensures operational management, with a cash commitment of 700 million dirhams to accelerate DMD’s growth.
With a turnover of 1.1 billion dirhams, a team of 250 employees, and a commercial presence in more than 65 countries, DMD is now ranked third among Moroccan players in the sector. Its purpose is to become a one-stop health shop in Morocco, offering an integrated solution covering the entire value chain and all therapeutic areas.
Finally, the international momentum is already underway with the opening of a subsidiary in Tunis, the first step in development on the African continent. DMD will present its African strategy and long-term ambitions at the Arab Health 2026 Exhibition in Dubai, thus confirming its role as a Moroccan leader in regional expansion.
